A new approach to coronary stenting, Svelte IDS and RX technologies reduce the steps, time, cost of procedures, and enhance patient outcomes. Learn more.
Total raised: $43M
Investors 3
Funding Rounds 3
Date | Series | Amount | Investors | Deal News |
19.03.2015 | - | $16M | - | finsmes.co... |
10.03.2014 | - | $5M | - | finsmes.co... |
31.10.2013 | - | $22M | - | finsmes.co... |
Mentions in press and media 25
Date | Title | Description | Category | Author | Source |
30.03.2022 | DSM Biomed... | Marc Hendriks, VP, Strategy an... | - | - | prweb.com/... |
17.10.2020 | OPTIMIZE S... | OPTIMIZE Pivotal Study 1 Year ... | - | Business W... | venturebea... |
10.01.2018 | Svelte Med... | OPTIMIZE is Evaluating the Wor... | - | Business W... | venturebea... |
16.05.2017 | Svelte Med... | First-in-Man Study Using the W... | - | Business W... | venturebea... |
24.10.2016 | Svelte Med... | DIRECT RX Combines a New Class... | - | Business W... | venturebea... |
07.06.2016 | Robert Fis... | Robert Fischell, a holder of m... | - | Business W... | venturebea... |
19.01.2016 | Svelte Med... | The World’s First Drug-Eluting... | - | Business W... | venturebea... |
15.12.2015 | Svelte Med... | The World’s First Drug-Eluting... | - | Business W... | venturebea... |
20.05.2015 | Svelte Med... | World’s First Drug-Eluting Cor... | - | Business W... | venturebea... |
19.03.2015 | Svelte Med... | Svelte Medical Systems, a New ... | USA | - | finsmes.co... |
Show more